| PB8 Stock | | | EUR 20.20 0.30 1.51% |
Director
Ms. Carol A. Wrenn serves as Independent Director of the company. Ms. Wrenn also serves as a member of the Audit Committee and the Compensation Committee. She is the founder and owner of Whitewater Advisors LLC which provides consulting services to small businesses. She was the founder and owner of Sky River Helicopters, LLC, a company that provides helicopter charters, tours, commercial services and lessons, from January 2010 until September 2015. She previously served as an Executive Vice President and the President of the Animal Health Division at Alpharma Inc., a human and animal pharmaceutical company, from November 2001 to June 2009. From April 2007 to April 2009, Ms. Wrenn also held the position of Chairman of the Animal Health Institute, an industry organization advocating for animal health issues, including efficient and effective FDA, USDA and EPA regulatory and approval processes. From January 2002 to June 2009, she was an active member of the Board of Directors of the International Federation of Animal Health. Prior to joining Alpharma, Ms. Wrenn held various executive positions at Honeywell International Inc. from 1984 to 2001. She served as Business Director of Honeywells Refrigerants, Fluorine Products Division from 2000 to 2001 and was the Commercial Director and Managing Director of Honeywells European Fluorochemical operations based in Haasrode, Belgium from 1997 to 2000. Ms. Wrenn also held a number of positions in sales, marketing, business development and finance during her tenure with AlliedSignal. Beginning in January 2013, Ms. Wrenn has served as a director of Heska Corporationrationration. She holds a Bachelors Degree from Union College, an MBA from Lehigh University and a DBA from California Southern University. Ms. Wrenn is qualified to serve on our Board of Directors due to her relevant industry experience, strategic and problemsolving skills and strong interpersonal and negotiation skills. since 2010.
| Age | 58 |
| Tenure | 15 years |
| Phone | 201 329 7300 |
| Web | https://www.pahc.com |
Phibro Animal Management Efficiency
The company has return on total asset
(ROA) of
0.0532 % which means that it generated a profit of $0.0532 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
0.1428 %, meaning that it generated $0.1428 on every $100 dollars invested by stockholders. Phibro Animal's management efficiency ratios could be used to measure how well Phibro Animal manages its routine affairs as well as how well it operates its assets and liabilities.
Phibro Animal Health has accumulated 417.93
M in total debt with debt to equity ratio
(D/E) of 1.8, which is about average as compared to similar companies. Phibro Animal Health has a current ratio of 2.98, suggesting that it is
liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Phibro Animal until it has trouble settling it off, either with new capital or with free cash flow. So, Phibro Animal's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Phibro Animal Health sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Phibro to invest in growth at high rates of return. When we think about Phibro Animal's use of debt, we should always consider it together with cash and equity.
Phibro Animal Health Corporation develops, manufactures, and supplies a range of animal health and mineral nutrition products for livestock primarily in the United States. Phibro Animal Health Corporation was incorporated in 2014 and is headquartered in Teaneck, New Jersey. PHIBRO ANIMAL operates under Drug ManufacturersSpecialty Generic classification in Germany and is traded on Frankfurt Stock Exchange. It employs 1725 people. Phibro Animal Health (PB8) is traded on Frankfurt Exchange in Germany and employs 1,860 people.
Management Performance
Phibro Animal Health Leadership Team
Elected by the shareholders, the Phibro Animal's board of directors comprises two types of representatives: Phibro Animal inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Phibro. The board's role is to monitor Phibro Animal's management team and ensure that shareholders' interests are well served. Phibro Animal's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Phibro Animal's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ramon Fuenmayor, Pres Region | |
| Larry Miller, Chief Operating Officer | |
| Thomas Dagger, Senior Vice President General Counsel, Corporate Secretary | |
| Jonathan Bendheim, Director and President MACIE Region and General Manager of Israel Operations | |
| E Corcoran, Independent Director | |
| Damian Finio, Chief Officer | |
| Jean Filippi, Pres Region | |
| Richard Johnson, Chief Financial Officer | |
| Gerald Carlson, Independent Director | |
| Mary Malanoski, Independent Director | |
| Rob Aukerman, President North America Region | |
| Jack Bendheim, Chairman of the Board, President, Chief Executive Officer, Director | |
| Daniel Bendheim, Executive Vice President, Corporate Strategy and Director | |
| Anthony Andolino, Vice President - Finance, Treasurer | |
| Sam Gejdenson, Independent Director | |
| Lisa Escudero, Senior Vice President of Human Resources | |
| Carol Wrenn, Independent Director | |
Phibro Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Phibro Animal a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Phibro Stock
When determining whether Phibro Animal Health offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Phibro Animal's
financial statements, including income statements, balance sheets, and cash flow statements, to assess its
financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Phibro Animal Health Stock.
Outlined below are crucial reports that will aid in making a well-informed decision on Phibro Animal Health Stock: Check out
Your Equity Center to better understand how to build diversified portfolios, which includes a position in Phibro Animal Health. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in board of governors.
You can also try the
Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Please note, there is a significant difference between Phibro Animal's value and its price as these two are different measures arrived at by different means. Investors typically determine if Phibro Animal is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Phibro Animal's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.